Abstract:Objective: Prostate cancer (PC) is the second leading cause of cancer death in men in the United States after lung cancer in global incidence. Elderly male patients over 65 years old account for more than 60% of PC patients, and the impact of surgical treatment on the prognosis of PC patients is controversial. Moreover, there are currently no predictive models that can predict the prognosis of elderly PC patients undergoing surgical treatment. Therefore, we aimed to construct a new nomogram to predict cancer-specific survival (CSS) in elderly PC patients undergoing surgical treatment. Methods: Data for surgically treated PC patients aged 65 years and older were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox regression models were used to identify independent risk factors for elderly PC patients undergoing surgical treatment. A nomogram of elderly PC patients undergoing surgical treatment was developed based on the multivariate Cox regression model. The consistency index (C-index), the area under the subject operating characteristic curve (AUC), and the calibration curve were used to test the accuracy and discrimination of the predictive model. Decision curve analysis (DCA) was used to examine the potential clinical value of this model. Results: A total of 44,975 elderly PC patients undergoing surgery in 2010–2018 were randomly assigned to the training set ( N = 31705) and validation set ( N = 13270). the training set was used for nomogram development and the validation set was used for internal validation. Univariate and multivariate Cox regression model analysis showed that age, marriage, TNM stage, surgical style, chemotherapy, radiotherapy, Gleason score(GS), and prostate-specific antigen(PSA) were independent risk factors for CSS in elderly PC patients undergoing surgical treatment. The C index of the training set and validation indices are 0.911(95%CI: 0.899–0.923) and 0.913(95%CI: 0.893–0.933), respectively, indicating that the nomogram has a good discrimination ability. The AUC and the calibration curves also show good accuracy and discriminability. Conclusions: To our knowledge, our nomogram is the first predictive model for elderly PC patients undergoing surgical treatment, filling the gap in current predictive models for this PC patient population. Our data comes from the SEER database, which is trustworthy and reliable. Moreover, our model has been internally validated in the validation set using the C-index,AUC and the and the calibration curve, showed that the model have good accuracy and reliability, which can help clinicians and patients make better clinical decision-making. Moreover, the DCA results show that our nomogram has a better potential clinical application value than the TNM staging system.

Are Prostate Biopsies Necessary for All Patients 75 Years and Older?

Optimizing Prostate Cancer Accumulating Model: Combined PI-RADS V2 with Prostate Specific Antigen and Its Derivative Data.

Development and External Multicenter Validation of Chinese Prostate Cancer Consortium Prostate Cancer Risk Calculator for Initial Prostate Biopsy.

Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography

Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study

Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy-naive men based on multi-institutional analysis

Development and validation of a nomogram to predict cancer-specific survival in nonsurgically treated elderly patients with prostate cancer

Validation Study of a Prostate Health Index-Based Nomogram Model for Predicting Prostate Cancer

MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 Ng/ml.

Influence of Age on Predictiveness of Genetic Risk Score for Prostate Cancer in a Chinese Hospital-Based Biopsy Cohort.

Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data

Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata

A Prostate Biopsy Strategy Based on a New Clinical Nomogram Reduces the Number of Biopsy Cores Required in High-Risk Patients

Age-Specific Prostate Specific Antigen Cutoffs For Guiding Biopsy Decision In Chinese Population

A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients Undergoing Surgery With Prostate Cancer: A Population-Based Study

Development and external validation of a prostate health index-based nomogram for predicting prostate cancer

A novel nomogram predicting the risk of positive biopsy for patients in the diagnostic gray area of prostate cancer

Development and Validation of a Nomogram Including Lymphocyte-to-Monocyte Ratio for Initial Prostate Biopsy: A Double-Center Retrospective Study

Gleason score, surgical and distant metastasis are associated with cancer-specific survival and overall survival in middle aged high-risk prostate cancer: A population-based study

Nomogram for predicting the overall survival of patients with early-onset prostate cancer: A population-based retrospective study